Wealthfront Advisers
BSX icon

Wealthfront Advisers’s Boston Scientific BSX Stock Holding History

Wealthfront Advisers’s Portfolio BSX Stock Details BSX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.25M Sell
76,210
-22,894
-23% -$1.24M 0.01% 529
2026
Q1 		$6.22M Sell
99,104
-27,180
-22% -$2.17M 0.01% 373
2025
Q4 		$12M Sell
126,284
-20,222
-14% -$1.98M 0.03% 217
2025
Q3 		$14.3M Sell
146,506
-1,589
-1% -$165K 0.03% 170
2025
Q2 		$15.9M Buy
148,095
+6,902
+5% +$698K 0.04% 145
2025
Q1 		$14.2M Buy
141,193
+27,075
+24% +$2.73M 0.04% 145
2024
Q4 		$10.2M Buy
114,118
+7,338
+7% +$646K 0.03% 183
2024
Q3 		$8.95M Buy
106,780
+3,032
+3% +$239K 0.03% 183
2024
Q2 		$7.99M Buy
103,748
+4,425
+4% +$324K 0.03% 180
2024
Q1 		$6.8M Buy
99,323
+2,520
+3% +$162K 0.02% 208
2023
Q4 		$5.6M Buy
96,803
+7,917
+9% +$423K 0.02% 218
2023
Q3 		$4.69M Buy
88,886
+5,887
+7% +$309K 0.02% 228
2023
Q2 		$4.49M Buy
82,999
+17,659
+27% +$922K 0.02% 238
2023
Q1 		$3.27M Buy
65,340
+7,920
+14% +$373K 0.01% 286
2022
Q4 		$2.66M Sell
57,420
-4,371
-7% -$189K 0.01% 332
2022
Q3 		$2.39M Buy
61,791
+24,002
+64% +$963K 0.01% 327
2022
Q2 		$1.41M Sell
37,789
-929
-2% -$37.8K 0.01% 437
2022
Q1 		$1.71M Buy
38,718
+3,307
+9% +$143K 0.01% 431
2021
Q4 		$1.5M Sell
35,411
-144
-0.4% -$6.05K 0.01% 441
2021
Q3 		$1.54M Buy
35,555
+4,476
+14% +$198K 0.01% 398
2021
Q2 		$1.33M Buy
31,079
+3,660
+13% +$154K 0.01% 387
2021
Q1 		$1.06M Buy
27,419
+5,916
+28% +$224K 0.01% 376
2020
Q4 		$773K Sell
21,503
-919
-4% -$33.1K ﹤0.01% 389
2020
Q3 		$857K Buy
22,422
+1,068
+5% +$41.2K 0.01% 356
2020
Q2 		$750K Sell
21,354
-625
-3% -$22.5K 0.01% 368
2020
Q1 		$717K Sell
21,979
-21,087
-49% -$824K 0.01% 335
2019
Q4 		$1.95M Sell
43,066
-883
-2% -$36.9K 0.01% 184
2019
Q3 		$1.79M Sell
43,949
-566
-1% -$24K 0.02% 190
2019
Q2 		$1.91M Sell
44,515
-3,416
-7% -$131K 0.02% 164
2019
Q1 		$1.84M Buy
47,931
+379
+0.8% +$14.5K 0.02% 164
2018
Q4 		$1.68M Buy
+47,552
New +$1.72M 0.02% 153

Other funds holding BSX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
BG
Bollard Group Boston, Massachusetts $3.29B AUM 4.86% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Amundi
Amundi Paris, France $413B AUM 44.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Wealthfront Advisers's BSX Position: Q2 2026 in Review

Wealthfront Advisers reduced its Boston Scientific (BSX) stake by 23% in Q2 2026, selling an estimated $1.24M and leaving 76,210 shares worth $3.25M. The position accounts for 0.01% of the portfolio, ranked #529.

Wealthfront Advisers first reported a position in BSX in Q4 2018 and has held it in 31 quarters since. The position peaked at $15.9M in Q2 2025. 1,039 funds tracked by Wall St. Rank hold BSX as of Q2 2026.

  • Wealthfront Advisers held 76,210 shares of Boston Scientific worth $3.25M as of Q2 2026.
  • Wealthfront Advisers sold 22,894 Boston Scientific shares in Q2 2026, an estimated $1.24M.
  • Boston Scientific made up 0.01% of Wealthfront Advisers's portfolio in Q2 2026, its #529 holding.
  • Wealthfront Advisers first reported a position in Boston Scientific in Q4 2018 and has held it in 31 quarters since.
  • Wealthfront Advisers's Boston Scientific position peaked at $15.9M in Q2 2025.
  • 1,039 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.

Based on Wealthfront Advisers's 13F filing for Q2 2026, filed 7 Aug 2026.